ADvantage Therapeutics Welcomes Esteemed Expert in Alzheimer’s Disease and Klotho Protein, Carmela Abraham, Ph.D. as Chief Science Officer
Dr. Abraham, a luminary in the fields of AD and aging, will complement ADvantage’s efforts to extend healthspan by delivering proprietary klotho-encoding mRNA.
- Dr. Abraham, a luminary in the fields of AD and aging, will complement ADvantage’s efforts to extend healthspan by delivering proprietary klotho-encoding mRNA.
- As part of this development, ADvantage Therapeutics has acquired important intellectual property assets including four patent applications from Klogenix, which Dr. Abraham co-founded with Menachem Abraham.
- Dr. Abraham has dedicated her career to unraveling the intricacies of aging and Alzheimer’s disease.
- Her groundbreaking work has shown that elevating klotho levels can enhance outcomes in mouse models of Alzheimer's disease, multiple sclerosis, and ALS.